Exact Sciences Co. (NASDAQ:EXAS) Shares Purchased by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. boosted its stake in Exact Sciences Co. (NASDAQ:EXAS) by 1.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,137,664 shares of the medical research company’s stock after acquiring an additional 17,555 shares during the period. Charles Schwab Investment Management Inc. owned 0.63% of Exact Sciences worth $106,827,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in EXAS. Park Place Capital Corp raised its holdings in shares of Exact Sciences by 189.2% during the first quarter. Park Place Capital Corp now owns 376 shares of the medical research company’s stock worth $25,000 after purchasing an additional 246 shares during the period. Raleigh Capital Management Inc. acquired a new stake in shares of Exact Sciences during the second quarter worth $37,000. TCI Wealth Advisors Inc. raised its holdings in shares of Exact Sciences by 15,466.7% during the first quarter. TCI Wealth Advisors Inc. now owns 467 shares of the medical research company’s stock worth $32,000 after purchasing an additional 464 shares during the period. Ameritas Advisory Services LLC acquired a new stake in shares of Exact Sciences during the first quarter worth $32,000. Finally, Private Trust Co. NA acquired a new stake in shares of Exact Sciences during the second quarter worth $45,000. 89.13% of the stock is owned by institutional investors and hedge funds.

Exact Sciences Price Performance

Shares of NASDAQ EXAS opened at $67.29 on Tuesday. Exact Sciences Co. has a twelve month low of $40.73 and a twelve month high of $100.77. The company has a current ratio of 2.41, a quick ratio of 2.13 and a debt-to-equity ratio of 0.74. The company has a market capitalization of $12.17 billion, a price-to-earnings ratio of -42.32 and a beta of 1.46. The firm has a 50-day moving average of $66.20 and a two-hundred day moving average of $79.81.

Insider Buying and Selling at Exact Sciences

In other Exact Sciences news, insider Everett Cunningham sold 13,007 shares of the company’s stock in a transaction dated Thursday, October 12th. The shares were sold at an average price of $66.49, for a total value of $864,835.43. Following the completion of the sale, the insider now directly owns 37,909 shares of the company’s stock, valued at approximately $2,520,569.41. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of analysts have weighed in on EXAS shares. Jefferies Financial Group increased their target price on shares of Exact Sciences from $100.00 to $110.00 and gave the stock a “buy” rating in a report on Thursday, August 3rd. Piper Sandler lowered their price target on shares of Exact Sciences from $90.00 to $80.00 and set an “overweight” rating for the company in a research report on Monday, October 16th. Robert W. Baird upped their price target on shares of Exact Sciences from $99.00 to $121.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 2nd. StockNews.com initiated coverage on shares of Exact Sciences in a research report on Thursday, October 5th. They set a “hold” rating for the company. Finally, The Goldman Sachs Group lowered their price target on shares of Exact Sciences from $100.00 to $90.00 and set a “buy” rating for the company in a research report on Friday, November 3rd. Five investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $96.56.

Exact Sciences Company Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.